Pharvaris Outlines 2025 Strategic Priorities

Core Insights - Pharvaris is focused on advancing the clinical development of deucrictibant, a novel oral bradykinin B2 receptor antagonist, to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema (AAE) [1][11] Strategic Priorities for 2025 - The company aims to execute two pivotal Phase 3 clinical studies for HAE, specifically RAPIDe-3 for on-demand treatment and CHAPTER-3 for prophylaxis, with topline data expected in 1Q2026 and 2H2026 respectively [2][4] - Pharvaris plans to expand its pipeline into AAE, with the initiation of a clinical study for acquired angioedema due to C1-INH deficiency anticipated in 2025 [3][6] - The company is operating from a strong financial position, with an estimated cash runway extending into 3Q2026 [3] Clinical Development Updates - RAPIDe-3 is a global Phase 3 study evaluating deucrictibant for the on-demand treatment of HAE attacks, targeting approximately 120 participants, with primary efficacy endpoints focused on symptom relief [2][5] - CHAPTER-3 is a randomized, double-blind, placebo-controlled Phase 3 study for prophylaxis against HAE attacks, aiming to enroll about 81 participants and evaluate the efficacy of deucrictibant compared to placebo [4] - An open-label extension study, CHAPTER-4, is set to initiate in 1Q2025 to further evaluate the long-term efficacy and tolerability of deucrictibant [4] Business Updates - The company has expanded its team to support the launch of deucrictibant, with new appointments in sales, marketing, and business development [8] - Pharvaris presented data on HAE treatment experiences and unmet needs at recent medical congresses, highlighting the demand for novel oral therapies [8] - Upcoming presentations at investor conferences and medical congresses are scheduled, including participation in the J.P. Morgan Healthcare Conference [9][13]